News • Corona and co
How the sun impacts the spread of viral respiratory diseases
Why do most viral epidemics spread cyclically in autumn and winter in the globe's temperate regions? The answer is intimately related to our sun.
Coronavirus
News • Among trillion possibilities
Rapid method finds potent COVID-19 antibody
University of Pittsburgh School of Medicine scientists have discovered the fastest way to identify potent, neutralizing human monoclonal antibodies against SARS-CoV-2, the virus that causes COVID-19.
News • International Day of Radiology 2020
IDoR dedicated to professionals fighting COVID-19
This year, the International Day of Radiology is dedicated to all imaging professionals and their essential role in fighting the COVID-19 pandemic, making an indispensable contribution to the diagnosis and treatment of COVID-19 patients.
News • Block of erythrocytes formation
SARS-CoV-2 might attack red marrow
Specialists from the Department of Fundamental Medicine of Far Eastern Federal University (FEFU) with Russian and Japanese colleagues have probed into mechanisms of COVID-19 inside-the-body distribution linked to erythrocytes damaging.
News • Autopsy study
Myocarditis linked to COVID-19 not as common as believed
A study conducted by Richard Vander Heide, MD, PhD, Professor and Director of Pathology Research at LSU Health New Orleans School of Medicine, and Marc Halushka, MD, PhD, Professor of Pathology at Johns Hopkins University School of Medicine, suggests myocarditis caused by COVID-19 may be a relatively rare occurrence.
News • Spanish study
Does vitamin D deficiency lead to severe COVID-19 cases?
Over 80 percent of 200 COVID-19 patients in a hospital in Spain have vitamin D deficiency, according to a new study.
News • Collaboration with Mammoth Biosciences
Merck to scale up new SARS-CoV-2 Test
Merck announced a collaboration with Mammoth Biosciences Inc. for the development, scale-up and commercial production of Mammoth’s CRISPR-based SARS CoV-2 diagnostic test.
News • British Covid-19 study
The more symptoms, the longer the antibodies remain
Asymptomatic coronavirus sufferers appear to lose detectable antibodies sooner than people who have exhibited COVID-19 symptoms, according to one of the biggest studies of its kind in Britain published on Tuesday.
News • Using virus particles in exhaled breath
New SARS-CoV-2 test to deliver results in under 5 minutes
Research and innovation hub Imec announced that it has started developing a groundbreaking SARS-CoV-2 test. Unlike current approaches (using blood, saliva, or a nasopharyngeal swab), the new test will identify SARS-CoV-2 virus particles in a person’s exhaled breath. The solution promises the accurate identification of a contagious case in less than five minutes.
News • Risk assessment
Understanding the spread of COVID-19 on public transport
Researchers at Newcastle University are involved in a study to understand the risks of COVID-19 transmission on public transport and to identify the best measures to control it. Known as Project TRACK (Transport Risk Assessment for Covid Knowledge), the study will conduct fieldwork on buses and trains in London, Leeds and Newcastle, including the Metro system in Tyne and Wear.
News • Immune reponse to COVID-19
‘Mini-lungs’ reveal early stages of SARS-CoV-2 infection
‘Mini-lungs’ grown from tissue donated to Cambridge hospitals has provided a team of scientists from South Korea and the UK with important insights into how COVID-19 damages the lungs. Writing in the journal Cell Stem Cell, the researchers detail the mechanisms underlying SARS-CoV-2 infection and the early innate immune response in the lungs.
News • Trial finds limited effectiveness
COVID-19: plasma from recovered patients not as effective as hoped
Convalescent plasma shows limited effectiveness as a potential treatment for patients with COVID-19 to help them fight off the infection, finds a clinical trial from India published by The BMJ. The findings show that convalescent plasma fails to reduce mortality or stop progression to severe COVID-19.
News • Flaws in study design
Will COVID-19 vaccines save lives? Right now, we cannot tell
Vaccines are being hailed as the solution to the COVID-19 pandemic, but the vaccine trials currently underway are not designed to tell us if they will save lives, reports Peter Doshi, Associate Editor at The BMJ. Several COVID-19 vaccine trials are now in their most advanced (phase 3) stage, but what will it mean exactly when a vaccine is declared “effective”? Many may assume that successful…
News • Neuropilin-1 as a 'helper' for COVID-19
Coronavirus: Study finds further 'door opener' into the cell
The coronavirus SARS-CoV-2 is known to infect cells via the receptor ACE2. An international research team under German-Finnish coordination has now identified neuropilin-1 as a factor that can facilitate SARS-CoV-2 entry into the cells’ interior. Neuropilin-1 is localized in the respiratory and olfactory epithelia, which could be a strategically important localization to contribute to…
News • 'QCOVID' model
New COVID-19 tool predicts risks of hospital admission and death
A new risk tool, developed by UK researchers to predict a person’s risk of being admitted to hospital and dying from COVID-19 has been published by The BMJ. With cases increasing in the UK and elsewhere, and winter approaching, there is an urgent need for reliable models that predict the likely course of COVID-19, to support decisions about shielding, hospital admission, treatment, and…
News • Therapy development
New approach to 'BEAT' COVID-19
The present Coronavirus pandemic with all its effects on society – both health and economic – highlights the urgency of developing new therapies for COVID-19 treatment. At the same time, it demonstrates the necessity to become well prepared for new virus infections we may be facing in the future. To help control the current pandemic and brace for novel pathogens that may cause future…
News • COVID immunity research
Coronavirus re-infection: what we know so far – and the vital missing clues
As President Trump claims that he is immune to COVID-19 and isolated reports emerge of reinfection, what is the truth about immunity to COVID-19? To date, there have been six published cases of COVID-19 reinfection, with various other unverified accounts from around the world. Although this is a comparably small fraction of the millions of people known to have been infected, should we be…
News • Infection with Covid-19
The antiviral effect of innate immunity
Innate immunity is the fastest-acting component of the immune system, but so far little is known about its role during infection with SARS-CoV-2. A few hours after an infection, the body emits an alarm signal, interferon, enabling cells that have not yet been infected to produce antiviral proteins. This phenomenon occurs well before the production of neutralizing antibodies. Scientists from the…
News • Interdisciplinary collaboration
CovidCorpus: Research database to boost battle against the coronavirus
Researchers around the world can tap into a new inter-disciplinary online database of COVID-19 research, allowing them to search for new partners, resources and funding to boost the global battle against the virus.
News • Uncommon, but reversible
Sudden deaf: permanent hearing loss linked to COVID-19
Although uncommon, sudden permanent hearing loss seems to be linked to COVID-19 infection in some people, warn doctors, reporting the first UK case in the journal BMJ Case Reports. Awareness of this possible side effect is important, because a prompt course of steroid treatment can reverse this disabling condition, they emphasise. Sudden hearing loss is frequently seen by ear, nose and throat…
Video • New insights on the virus' ‘survivability’
How long does SARS-CoV-2 last on surfaces?
Researchers at CSIRO, Australia's national science agency, have found that SARS-CoV-2, the virus responsible for COVID-19, can survive for up to 28 days on common surfaces including banknotes, glass – such as that found on mobile phone screens - and stainless steel.
News • Simulation model for pathological mechanisms
Understanding the progress of viral infections
It is only 120 millionths of a millimetre in size but can bring entire countries to a standstill: the Corona virus. Even if it were to disappear one day, viral infections will still be among the most frequent and difficult-to-treat diseases in humans. Even decades of research have only produced a few standardized vaccines and strategies for treatment to combat just a small number of viruses. Nor…
News • Interrelationship
Impact of COVID-19 on cancer treatment
The COVID-19 pandemic has impacted virtually every aspect of cancer care and research– from introducing new risks for cancer patients to disrupting the delivery of cancer treatment and the continuity of cancer research.
News • Using artificial lungs
How COVID-19 causes blood clots
Scientists at EPFL are using technology to better understand how coronavirus causes blood clots in some patients. They have developed a simplified model of a lung that lets them observe, for the first time, how the virus attacks the cells lining blood vessels.
News • Strict separation policy
Creating 'COVID-19 free' hospital areas to save lives after surgery
Setting up ‘COVID-19 free’ hospital areas for surgical patients could save lives during the second wave of the pandemic – reducing the risk of death from lung infections associated with coronavirus, a new global study reveals. Researchers working together in Brazil and beyond found that that patients who had their operation and hospital care in ‘COVID-19 free’ areas had better outcomes.…